ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2063

Training to Increase Minority Enrollment in Lupus Clinical Trials with CommunitY Engagement (TIMELY): Assessing Behavioral Predictors of Clinical Trial Referrals Among Healthcare Providers

Saira Sheikh1, Tessa Englund1, Andrew Simkus2, Nicole Wanty3, Annie McNeill4, Kristen Holtz4, Tenesha Hood5, Starla Blanks6, Maria Allen7 and Allen Anandarajah7, 1University of North Carolina at Chapel Hill, Chapel Hill, NC, 2KDH Research & Communication, Asheville, NC, 3KDH Research & Communication, Marietta, GA, 4KDH Research & Communication, Atlanta, GA, 5ACR, Atlanta, GA, 6American College of Rheumatology, Atlanta, GA, 7University of Rochester Medical Center, Rochester, NY

Meeting: ACR Convergence 2023

Keywords: clinical trial, Community programs, Disparities, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 14, 2023

Title: (2061–2088) Professional Education Poster

Session Type: Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: The aim of this study is to assess outcomes among healthcare providers in the American College of Rheumatology’s (ACR) Training to Increase Minority Enrollment in Lupus Clinical Trials with CommunitY Engagement (TIMELY) program. The TIMELY program was designed to improve engagement of healthcare providers and therefore promote referrals of underrepresented patients with lupus to clinical trials (LCTs). Enrolled providers participated in two components of the TIMELY program: 1) The ACR’s Materials to Increase Minority Involvement in Clinical Trials (MIMICT) continuing medical education (CME) course; and 2) Roundtable meetings where providers learned about and discussed barriers, strategies, and opportunities to advance participation of underrepresented patients in LCTs.

Methods: This roundtable study used an online survey to evaluate pre-post changes in theory-based behavioral predictors of clinical trial referrals, including attitudes, self-efficacy, and intentions to refer underrepresented patients to LCTs. Research teams at two participating sites, the University of North Carolina at Chapel Hill (UNC) and University of Rochester Medical Center (URMC), began enrollment in June 2022 and implemented the TIMELY roundtables between September 2022 and April 2023. Community members, community health workers, and advisory committee members provided extensive support and guidance to facilitate TIMELY roundtable implementation. In conjunction with the ACR, sites recruited participants and hosted roundtables in-person and online with regional providers who care for patients with lupus. Providers completed a baseline survey prior to roundtable participation, and post-roundtable, and 3-month follow-up surveys. We conducted paired t-tests between baseline and follow-up to assess differences in composite scores and individual measures for each outcome.

Results: As of April 2023, the sample included 35 providers. From baseline to follow-up, composite scores for self-efficacy increased from 6.62 to 7.42 (p< 0.01) and composite scores for intentions increased from 7.14 to 8.21 (p=0.001).

Conclusion: These promising findings highlight the potential of the TIMELY program to improve theory-based behavioral predictors of provider referrals of underrepresented patients to LCTs.


Disclosures: S. Sheikh: AstraZeneca, 2, Aurinia Pharmaceuticals Inc., 2, Biogen, 2, GSK, 1, 1, 2, Lilly USA, 2, Pfizer, 5; T. Englund: None; A. Simkus: None; N. Wanty: None; A. McNeill: None; K. Holtz: None; T. Hood: None; S. Blanks: None; M. Allen: None; A. Anandarajah: None.

To cite this abstract in AMA style:

Sheikh S, Englund T, Simkus A, Wanty N, McNeill A, Holtz K, Hood T, Blanks S, Allen M, Anandarajah A. Training to Increase Minority Enrollment in Lupus Clinical Trials with CommunitY Engagement (TIMELY): Assessing Behavioral Predictors of Clinical Trial Referrals Among Healthcare Providers [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/training-to-increase-minority-enrollment-in-lupus-clinical-trials-with-community-engagement-timely-assessing-behavioral-predictors-of-clinical-trial-referrals-among-healthcare-providers/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/training-to-increase-minority-enrollment-in-lupus-clinical-trials-with-community-engagement-timely-assessing-behavioral-predictors-of-clinical-trial-referrals-among-healthcare-providers/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology